NLS drug-2

Spago Nanomedical has received regulatory approval to initiate a Phase IIa clinical study with its MRI contrast agent SN132D in endometriosis. Patient recruitment has started, and the first patient is expected to be dosed shortly. The ongoing SPAGOPIX-01 study in breast cancer has now been concluded and a final report is in preparation, states the […]

Evaxion Biotech has announced clinical data from the first-in-human study of its DNA-based cancer immunotherapy, EVX-02. In the clinical study, EVX-02 is given in combination with a checkpoint inhibitor and targets cancer mutations, neoantigens, in patients with resected melanoma. The company reported encouraging interim safety and immunogenicity data from the Phase 1/2a study of its […]

EpiEndo Pharmaceuticals has received regulatory approval to commence a Phase 2a clinical trial with lead molecule EP395 in COPD (Chronic Obstructive Pulmonary Disease) patients. EP395 is an orally available macrolide or ‘Barriolide,’ with reduced antimicrobial resistance potential, which aims to address the unmet medical need for a treatment for COPD. “This is the first time […]

Affibody’s licensee Rallybio Corporation has announced positive topline results from a Phase 1 single ascending dose (SAD) study in healthy participants of RLYB116. In the ongoing Phase 1 study, all study participants that were administered a single 1 mL subcutaneous injection of 100 mg of RLYB116 (n=6) demonstrated a reduction in free C5 greater than […]